Evaluation of 4-Amino-5-benzofuran-2-oyl-2-(4-methoxyphenyl)aminothiazole for antidiabetic applications: an in vitro and in vivo study

Subject Areas :

Priya Rani M ¹ , Akhila V. R ² , Krishnapriya, K. G ³ , Rajasekharan, K. N ⁴

1 - Department of Chemistry, University of Kerala, Kariavattom campus, Thiruvananthapuram 695 581, Kerala, India
2 - Department of Chemistry, University of Kerala, Kariavattom campus, Thiruvananthapuram 695 581, Kerala, India
3 - Department of Chemistry, University of Kerala, Kariavattom campus, Thiruvananthapuram 695 581, Kerala, India
4 - Department of Chemistry, University of Kerala, Kariavattom campus, Thiruvananthapuram 695 581, Kerala, India

Received: 2021-06-03 Accepted : 2021-06-03 Published : 2019-06-01

Keywords: 4-Amino-5-benzofuran-2-oyl-2-(4-methoxyphenyl)aminothiazole, Glucose uptake, Glut 4, SGOT, SGPT, liver marker enzymes,

Abstract :

The aim of the present study is to investigate the in vitro and in vivo antidiabetic activity of 4-amino-5-benzofuran-2-oyl-2-(4-methoxyphenyl)aminothiazole. Toxicity and in vitro antidiabetic study of the compound was carried out in L6 cell lines. In vivo antidiabetic studies were carried out in alloxan induced diabetic Wistar albino rats. In toxicity study, the compound showed an IC50 value of 973.62 µM. Significant changes in glucose uptake and Glut 4 translocation by 4-amino-5-benzofuran-2-oyl-2-(4-methoxyphenyl)aminothiazole suggested that the molecular mechanism of action is similar to that of insulin. In vivo treatment with 4-amino-5-benzofuran-2-oyl-2-(4-methoxyphenyl)aminothiazole at a concentration of 60 mg/kg bodyweight significantly decreased blood glucose and glycosylated haemoglobin levels in diabetic rats than in non-diabetic control rats. Oral administration of 4-amino-5-benzofuran-2-oyl-2-(4-methoxyphenyl)aminothiazole to the experimental groups also showed a highly significant reduction in total cholesterol level when compared with diabetic control rats These findings revealed that 4-amino-5-benzofuran-2-oyl-2-(4-methoxyphenyl)aminothiazole can be considered as a lead molecule for the control of type II diabetes.